Country: Canada
Language: English
Source: Health Canada
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE)
SANDOZ CANADA INCORPORATED
M05BA07
RISEDRONIC ACID
35MG
TABLET
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35MG
ORAL
100
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0135301003; AHFS:
APPROVED
2010-07-28
______________________________________________________________________________________________ _ _ Sandoz Risedronate (risedronate sodium) Page 1 of 40 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR SANDOZ RISEDRONATE Risedronate Sodium (as the hemi-pentahydrate) Tablets Tablets, 35 mg, oral Bisphosphonates (ATC Code: M05BA07) Sandoz Canada Inc. 110 Rue de Lauzon Boucherville, QC J4B 1E6 Date of Initial Authorization: July 28, 2010 Date of Revision: February 22, 2023 Submission Control Number: 267804 ______________________________________________________________________________________________ _ _ Sandoz Risedronate (risedronate sodium) Page 2 of 40 _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS 02/2023 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS................................................................................................................... 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS...................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Do Read the complete document